Bio/Pharma Business

Thermo Fisher Scientific Expands Proteomics Services with Olink Acquisition

July 13, 2024

Thermo Fisher will add Olink to its Life Sciences Solutions business.

Pfizer and Evotec Partner for Drug Discovery

July 12, 2024

Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.

uniQure to Sell Its Commercial Gene Therapy Manufacturing Operations in Massachusetts to Genezen

July 10, 2024

The acquisition of uniQure’s Lexington, Mass., manufacturing operations will boost Genezen’s late-phase and commercial gene therapy development and manufacturing services.

GSK and CureVac Enter into Licensing Agreement

July 04, 2024

The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.

Cell-Free Protein Synthesis Technology to be Made More Accessible Through LenioBio and Labscoop Partnership

July 04, 2024

LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.

Aurigene to Provide Cell Therapy Discovery Services to Edity to Support Clinical Development

July 02, 2024

This collaboration aims to support and accelerate clinical development of advanced and novel technologies.

AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition

June 29, 2024

This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.

Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets

June 28, 2024

Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.

Lantheus Acquires Rights to Life Molecular’s RM2 Targeting GRPR for Prostate and Breast Cancers

June 27, 2024

GRPR, or gastrin-releasing peptide receptor, is part of the bombesin G protein-coupled receptor family and has been found to be overexpressed in multiple cancers.

Novo Nordisk Aims to Invest $4.1 Billion to Expand Manufacturing Capacity in US

June 27, 2024

This $4.1 billion investment to build a second fill/finish manufacturing facility in Clayton, N.C., boosts Novo Nordisk's current 2024 investments in production to $6.8 billion.